BMRN vs. JNJ: BioMarin Pharmaceutical vs. Johnson & Johnson Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Johnson & Johnson (JNJ) reports 20.02%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Johnson & Johnson (JNJ) reports 16.20%, ranking against industry peers normally.

Both BioMarin Pharmaceutical (BMRN) at 26.58% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while BioMarin Pharmaceutical (BMRN) at -18.55% is closer to the peer norm — faster per-share earnings growth for JNJ.

Growth Metrics

Financial Strength

Both BioMarin Pharmaceutical (BMRN) at 2.44 and Johnson & Johnson (JNJ) at 1.02 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Johnson & Johnson (JNJ) at 0.55 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Johnson & Johnson (JNJ) trades at 41.92 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Johnson & Johnson (JNJ) at 6.69 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Johnson & Johnson (JNJ) at 8.16 carries an above-peer premium to book — JNJ is pricier on assets.

Valuation Metrics